Viridian Therapeutics, Inc. (VRDN)
Nasdaq · Healthcare · Biotechnology
$19.00−2.06%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.2B
- 52-week range
- $13.18 – $34.29
- 52-week change
- −6.87%
- EPS (trailing)
- −$3.39
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $70.8M (+23359.93%)
- Net income
- −$343M
- Operating margin
- −512.9%
- Free cash flow
- −$277M
From the company’s annual report on SEC EDGAR.
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 252 employees · viridiantherapeutics.com